VivoSeq
Oncology

Metastatic Ewing Sarcoma

15

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Metastatic Ewing Sarcoma is an emerging landscape with 15 programs across 10 companies. The most active players are Bristol-Myers Squibb, Meitheal, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 9 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1M

Meitheal

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 3A

Avyxa

1 program

Phase 3G

German Society for Pediatric Oncology and Hematology GPOH gGmbH

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT07194044·15 enrolled
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02306161·312 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)